Zepbound (tirzepatide for weight management) Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition
In addition, PEGylation reduces the clearance of protein drugs by reticuloendothelial tissue, shields antigenic determinants, reduces immune system recognition, and prevents degradation by proteolytic enzymes
The good news is this is entirely preventable
Recovery follows a consistent pattern, with fine vellus hairs appearing initially, followed by fuller regrowth within 6-12 months of initial shedding
Healthcare providers should consider BP therapy as a potential option for NF1 patients with significant bone complications, while also monitoring for possible adverse effects
The worst response to a plateau is a scramble